The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the manag...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: McNeel, Douglas G., Bander, Neil H., Beer, Tomasz M., Drake, Charles G., Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip W., Madan, Ravi A., Oh, William K., Peace, David J., Petrylak, Daniel P., Porterfield, Hank, Sartor, Oliver, Shore, Neal D., Slovin, Susan F., Stein, Mark N., Vieweg, Johannes, Gulley, James L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2016
Soggetti:
Position Article and Guidelines
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5170901/
https://ncbi.nlm.nih.gov/pubmed/28031820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0198-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi